Cel-Sci opened higher at $1.33, compared with its previous close of $1.31. In the last trading session, the stock traded between $1.19 and $1.35. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Cel-Sci is now worth
$ 0.34
Resulting in a loss of
$ 99.66 (99.66%)
Note: Past profits do not guarantee future returns.
No analyst rating data available.
Today's Change
$-0.11 (-8.17%)
Day High
$1.35
Day Low
$1.19
Day Open
$1.33
Prev Close
$1.31
Volume
1,47,980
1W Return
-13.58%
1M Return
-34.62%
3M Return
-20.33%
6M Return
-14.68%
1Y Return
-83.01%
Market Cap ($ Mn)
21
PE Ratio
-
PB Ratio
2.50
PEG Ratio
-
ROE
-230.36%
ROCE
-128.10%
EPS (TTM)
$-0.32
1 Week
-13.58%
1 Month
-34.62%
3 Months
-20.33%
6 Months
-14.68%
9 Months
-75.25%
CEL-SCI Q3 Results: Per-share loss narrows 65% YoY to $(0.47)
CEL-SCI reported a Q3 per-share loss of $(0.47), down 65.44% from the $(1.36) loss in the prior year period. This reflects a significant year-over-year improvement in the company's loss position.
2mo agoCEL-SCI study shows Multikine boosts 5-year survival to 73.4% in oral cancer
CEL-SCI Corporation published a study in Oral Oncology showing Multikine improves five-year overall survival to 73.4% versus 45.8% for standard care in biomarker-selected oral cancer patients. The data supports the company's upcoming global Confirmatory Registration Study targeting patients with low or zero PD-L1 expression and no lymph node involvement.
3mo agoCEL-SCI to launch Phase 3 confirmatory study for Multikine
CEL-SCI will initiate a 212-patient Phase 3 confirmatory study for Multikine, targeting global enrollment to validate a 66% reduction in death risk. The trial aims to confirm a 73% 5-year survival rate compared to standard of care alone, with potential for early FDA approval based on pre-surgical tumor responses.
4mo agoCEL-SCI closes $2.5M offering to fund Multikine
CEL-SCI Corporation successfully closed a best-efforts offering of 2,500,000 shares of common stock at $1.00 per share, generating approximately $2.5 million in gross proceeds. The capital will be allocated for the continued development of Multikine, general corporate purposes, and working capital, with ThinkEquity serving as the sole placement agent.
4mo agoCEL-SCI advances Multikine via dual-track strategy in US and Saudi Arabia
CEL-SCI Corporation is advancing Multikine through parallel regulatory pathways, initiating a confirmatory study in the U.S. targeting 212 patients and forming a strategic partnership with Saudi Amarox for Saudi Arabia. The U.S. study aims to replicate a 73% five-year survival rate, while the Saudi partnership offers a 50% revenue share and potential expansion into GCC countries.
4mo agoCEL-SCI and Saudi Amarox sign deal for Multikine in Saudi Arabia
CEL-SCI Corporation and Saudi Amarox are advancing a strategic agreement to commercialize Multikine in Saudi Arabia, marked by a signing ceremony at BIO 2026. The partnership features a 50/50 revenue share and positions Saudi Amarox as the exclusive distributor upon SFDA approval, with options for GCC expansion.
5mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Cel-Sci is now worth
$ 0.34
Resulting in a loss of
$ 99.66 (99.66%)
Note: Past profits do not guarantee future returns.
